# Oliver Gautschi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/oliver-gautschi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,463 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 62 |
| i10-index | 186 |
| OpenAlex ID | https://openalex.org/A5070375776 |
| ORCID iD | https://orcid.org/0009-0000-3137-3254 |
| Works | 484 |

## Researcher papers

- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives](https://scholariq.org/papers/lung-cancer-that-harbors-an-i-her2-i-mutation-epidemiologic-characteristics-and/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)
- [Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients](https://scholariq.org/papers/immune-checkpoint-inhibitors-associated-with-interstitial-lung-disease-in-cancer/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)
- [Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort](https://scholariq.org/papers/lung-cancer-patients-with-her2-mutations-treated-with-chemotherapy-and-her2/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Spine and Intervertebral Disc Pathology](https://scholariq.org/topics/spine-and-intervertebral-disc-pathology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.